S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NYSEAMERICAN:IGC

IGC Pharma (IGC) Stock Forecast, Price & News

$0.30
-0.01 (-3.22%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.30
$0.32
50-Day Range
N/A
52-Week Range
$0.28
$0.74
Volume
124,205 shs
Average Volume
136,655 shs
Market Capitalization
$15.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IGC stock logo

About IGC Pharma (NYSEAMERICAN:IGC) Stock

IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

IGC Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
IGC Pharma to Present at LD Micro Invitational XIII
8-K: IGC Pharma, Inc.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
IGC Pharma to Attend Investor Summit
IGC.P - | Stock Price & Latest News | Reuters
IGC Receives No Objection Letter from Health Canada
IGC Announces Updated Life Sciences Presentation
See More Headlines

IGC Price History

IGC Company Calendar

Last Earnings
2/10/2020
Today
6/10/2023
Next Earnings (Estimated)
6/21/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Electronic parts & equipment, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IGC
Employees
50
Year Founded
N/A

Profitability

Net Income
$-15,020,000.00
Net Margins
-1,610.48%
Pretax Margin
-1,610.48%

Debt

Sales & Book Value

Annual Sales
$400,000.00
Book Value
$0.47 per share

Miscellaneous

Free Float
44,850,000
Market Cap
$15.98 million
Optionable
Optionable
Beta
2.32

Key Executives

  • Ram Mukunda
    President, Chief Executive Officer & Director
  • Claudia Grimaldi
    CFO, Director, Chief Compliance Officer & VP
  • Jagadeesh Rao
    Chief Scientific Officer
  • Rohit Goel
    Chief Accounting Officer













IGC Stock - Frequently Asked Questions

How have IGC shares performed in 2023?

IGC Pharma's stock was trading at $0.40 at the beginning of the year. Since then, IGC shares have decreased by 24.8% and is now trading at $0.3010.
View the best growth stocks for 2023 here
.

Are investors shorting IGC Pharma?

IGC Pharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 896,700 shares, a decrease of 14.6% from the April 30th total of 1,050,000 shares. Based on an average daily volume of 102,400 shares, the days-to-cover ratio is currently 8.8 days.
View IGC Pharma's Short Interest
.

When is IGC Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023.
View our IGC earnings forecast
.

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its quarterly earnings data on Monday, February, 10th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The construction company earned $0.57 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 66.26% and a negative net margin of 1,610.48%.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

What is IGC Pharma's stock symbol?

IGC Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IGC."

Who are IGC Pharma's major shareholders?

IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins.
View institutional ownership trends
.

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGC Pharma's stock price today?

One share of IGC stock can currently be purchased for approximately $0.30.

How much money does IGC Pharma make?

IGC Pharma (NYSEAMERICAN:IGC) has a market capitalization of $15.98 million and generates $400,000.00 in revenue each year. The construction company earns $-15,020,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How can I contact IGC Pharma?

IGC Pharma's mailing address is 4336 Montgomery Ave, BETHESDA, MD 20814-4443, United States. The official website for the company is www.igcinc.us. The construction company can be reached via phone at (301) 983-0998, via email at info@igcinc.us, or via fax at 240-465-0273.

This page (NYSEAMERICAN:IGC) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -